Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
10,640
-100 (-0.93%)
Feb 18, 2026, 5:27 PM IDT
Market Cap124.16B +76.1%
Revenue (ttm)55.02B +4.3%
Net Income4.50B
EPS3.86
Shares Outn/a
PE Ratio27.62
Forward PE12.76
Dividendn/a
Ex-Dividend Daten/a
Volume1,120,108
Average Volume1,932,114
Open10,720
Previous Close10,740
Day's Range10,470 - 10,730
52-Week Range4,865 - 11,350
Beta0.72
RSI56.03
Earnings DateJan 28, 2026

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 32,842
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Truist Securities Raises Price Target for TEVA, Maintains Buy Rating | TEVA Stock News

Truist Securities Raises Price Target for TEVA, Maintains Buy Rating | TEVA Stock News

16 hours ago - GuruFocus

Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow

2026-02-17. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with this event.

1 day ago - Seeking Alpha

Sanofi, Teva Report Positive Phase 2b Results For Duvakitug

(RTTNews) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerative coliti...

1 day ago - Nasdaq

Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) will hold an investor call and webcast today to highlight new Phase 2b maintenance data for Duvakitug. The investigational thera...

1 day ago - Nasdaq

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study. Positive Data Fr...

1 day ago - Benzinga

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Teva and Sanofi SA (NASDAQ: SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.

1 day ago - Benzinga

Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's

Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's

1 day ago - GuruFocus

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tole...

1 day ago - Benzinga

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug sh...

1 day ago - Benzinga

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.

1 day ago - GlobeNewsWire

Harel Insurance Investments & Financial Services Ltd. ...

Harel Insurance Investments & Financial Services Ltd. Increases Stake in Teva Pharmaceutical Industries Ltd.

5 days ago - GuruFocus

Noteworthy ETF Inflows: SPDW, SPOT, SE, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...

7 days ago - Nasdaq

TEVA: Goldman Sachs Raises Price Target to $45, Maintains Buy Rating | TEVA Stock News

TEVA: Goldman Sachs Raises Price Target to $45, Maintains Buy Rating | TEVA Stock News

9 days ago - GuruFocus

Teva (TEVA) Q4 2024 Earnings Call Transcript

Teva (TEVA) Q4 2024 Earnings Call Transcript

13 days ago - The Motley Fool

Teva (TEVA) Q3 2024 Earnings Call Transcript

Teva (TEVA) Q3 2024 Earnings Call Transcript

13 days ago - The Motley Fool

A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings

In the current market session, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock price is at $34.94, after a 0.33% drop. However, over the past month, the company's stock went up by 7.18% , and in th...

13 days ago - Benzinga

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Down 0% on Feb 5

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Down 0% on Feb 5

13 days ago - GuruFocus

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

15 days ago - GuruFocus

Teva Pharmaceutical Industries Ltd (TEVA) Shares Up 3.39% on Feb 3

Teva Pharmaceutical Industries Ltd (TEVA) Shares Up 3.39% on Feb 3

15 days ago - GuruFocus

Notable ETF Inflow Detected - IDEV, SPOT, SE, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) w...

15 days ago - Nasdaq

Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

17 days ago - GuruFocus

Barclays Raises Price Target for TEVA to $38, Maintains Overweight Rating | TEVA Stock News

Barclays Raises Price Target for TEVA to $38, Maintains Overweight Rating | TEVA Stock News

19 days ago - GuruFocus

Teva snaps six straight sessions of gains

20 days ago - Seeking Alpha